Compounded vs Brand Semaglutide: Real Differences

What "compounded" actually means

A compounded medication is one prepared by a licensed pharmacy for an individual patient, typically because the commercial product is unavailable, the patient needs a different dose or formulation, or the patient has an allergy to an inactive ingredient in the commercial version. Compounding has a long legitimate history in pharmacy practice.

Compounded semaglutide became widely available during the FDA's declared shortage of brand-name semaglutide between 2022 and 2024. Under federal law, compounders are permitted to prepare otherwise commercially available drugs only when those drugs are on the FDA's shortage list. Once semaglutide was declared resolved off the shortage list in early 2024 and again in late 2024, the legal pathway for compounding large volumes of it narrowed substantially.

What brand-name semaglutide is

Wegovy® and Ozempic® are FDA-approved semaglutide formulations manufactured by Novo Nordisk. The molecule is the same in both; the indication, available dose strengths, and packaging differ. Rybelsus® is the oral formulation. Each goes through the standard FDA approval pathway: defined manufacturing process, defined supply chain, defined excipients, defined potency and purity controls, defined stability testing, and the full apparatus of post-marketing surveillance.

The active ingredient is a 31-amino-acid peptide with two specific modifications that extend its half-life. The manufacturing process is proprietary and difficult.

How the products actually differ

The clearest difference is regulatory oversight. FDA-approved semaglutide is reviewed before it reaches patients. Compounded products are not reviewed by the FDA on a per-product basis; oversight depends on the type of compounding pharmacy and the state board of pharmacy.

A second difference is the source of the active pharmaceutical ingredient. Brand-name semaglutide uses Novo Nordisk's proprietary semaglutide. Compounded products use semaglutide synthesized by other suppliers, some of which are FDA-registered API facilities and some of which are not. The FDA has issued warnings about counterfeit and adulterated semaglutide in the unregulated supply chain.

Some compounded products are not semaglutide at all. They may be semaglutide sodium or semaglutide acetate, which are salt forms that have not been tested for safety or efficacy in humans. The FDA has explicitly warned against these. They may also contain different excipients, different concentrations, and different stability profiles than the brand product.

Cost is the third meaningful difference. Cash price for compounded semaglutide has typically been a fraction of the brand cost, which is the main reason patients pursue it. Insurance coverage for the brand product is highly variable; the list price is high.

What the published evidence shows

The pivotal trials for weight loss (STEP for semaglutide, SURMOUNT for tirzepatide) studied the brand-manufactured products at the doses on the approved label. There is no equivalent clinical trial evidence for compounded versions. The assumption that a compounded version will produce the same outcomes as the brand product is plausible if the molecule is genuinely identical and the dose is accurate, but it is an assumption, not a demonstrated finding.

Adverse events from compounded GLP-1 products have been reported to the FDA, including dosing errors (often because compounded products use different concentrations than the brand product), hospitalizations from accidental overdose, and several deaths. The FDA does not have a clean numerator and denominator for comparative safety; the data are reports, not a controlled comparison.

The dosing-error problem

Brand-name semaglutide pens are pre-set to deliver specific dose increments. Compounded semaglutide is often supplied in a vial with a syringe, requiring the patient to draw up the dose themselves. Compounded products also frequently use a different concentration than the brand product, which means dose conversions between the two are not one-to-one. Several reported adverse events trace to patients drawing up what they believed was an equivalent dose without recognizing the concentration difference.

Where the picture sits now

As of mid-2026, compounded semaglutide is in a more constrained legal position than during the peak of the shortage. Some compounding pharmacies have continued to offer it under specific medical-necessity exceptions; others have shifted to compounding tirzepatide or other peptides. Several major telehealth platforms have moved to brand-only models or discontinued GLP-1 services entirely. The picture is fluid and varies by state.

Tirzepatide was declared off shortage by the FDA in late 2024, narrowing the compounding pathway for that molecule as well. A subset of compounding pharmacies have continued to prepare both molecules under interpretations of federal law that the FDA has publicly contested.

When to seek medical advice

Before starting or switching between compounded and brand semaglutide, talk to a clinician who actually knows the dose conversion math and the source of the compounded product. Independently verifying the compounding pharmacy's licensing through the state board of pharmacy is reasonable due diligence. Any product purchased outside a licensed pharmacy, including peptides marketed as "research chemicals," is not legitimately compounded and should not be injected.

Signs of an injection-site infection, severe allergic reaction, or unexpected severity of side effects should prompt immediate medical evaluation, and the prescriber should be told which exact product (brand or compounded, source pharmacy, concentration) is in use.

---

Wegovy®, Ozempic®, Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® are trademarks of Eli Lilly and Company. PepAI is independent.